Arrow Lab

Arrowhead Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient delivery modes, the company's therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. Its proprietary TRiM (Targeted RNAi Molecule) platform utilizes a novel structural design to optimize delivery to various tissue types, including the liver, lung, and muscle. Arrowhead's pipeline includes several advanced programs targeting cardiovascular disease, liver disease, and rare genetic disorders, with multiple candidates in late-stage clinical trials.